X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Newspaper Article (64222) 64222
Journal Article (13815) 13815
Newsletter (11140) 11140
Trade Publication Article (7346) 7346
Magazine Article (5737) 5737
Web Resource (4374) 4374
Book Review (826) 826
Transcript (755) 755
Report (577) 577
Publication (563) 563
Government Document (161) 161
Book Chapter (157) 157
Book / eBook (143) 143
Conference Proceeding (139) 139
Dissertation (114) 114
Reference (40) 40
Streaming Video (32) 32
Paper (26) 26
Journal / eJournal (8) 8
Data Set (7) 7
Market Research (4) 4
Electronic Resource (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
generic drugs (94901) 94901
pharmaceutical industry (51878) 51878
prescription drugs (9155) 9155
generic products (7800) 7800
fda approval (7079) 7079
pharmaceuticals (6511) 6511
patents (6494) 6494
drugs (6397) 6397
earnings per share (6289) 6289
corporate profits (5511) 5511
humans (5377) 5377
acquisitions & mergers (5159) 5159
index medicus (5060) 5060
chief executive officers (4988) 4988
intellectual property (4532) 4532
stock exchanges (4267) 4267
competition (4055) 4055
laboratories (3993) 3993
drug approval (3568) 3568
investments (3463) 3463
business metrics (3337) 3337
research & development--r&d (3311) 3311
drug stores (3272) 3272
manufacturing (3241) 3241
marketing (3125) 3125
reports (3039) 3039
stockholders (3009) 3009
pharmacy (3001) 3001
prices (2985) 2985
laws, regulations and rules (2821) 2821
brand names (2808) 2808
litigation (2801) 2801
product development (2760) 2760
present value (2534) 2534
profit margins (2425) 2425
medicare (2129) 2129
cost control (2107) 2107
health care policy (2036) 2036
cancer (2019) 2019
clinical trials (1993) 1993
agreements (1929) 1929
womens health (1927) 1927
capital gains (1923) 1923
patients (1903) 1903
financial performance (1894) 1894
drug therapy (1880) 1880
prescribing (1844) 1844
drugs, generic - economics (1807) 1807
regulatory approval (1800) 1800
capital losses (1781) 1781
forecasts and trends (1749) 1749
united states (1736) 1736
sales (1735) 1735
biotechnology industry (1730) 1730
stock prices (1725) 1725
drug dosages (1714) 1714
pharmacology & pharmacy (1704) 1704
appointments & personnel changes (1699) 1699
research (1645) 1645
costs (1609) 1609
market entry (1599) 1599
medical research (1576) 1576
biological products (1574) 1574
male (1568) 1568
institutional investments (1541) 1541
female (1518) 1518
market research (1517) 1517
studies (1497) 1497
dividends (1472) 1472
pharmacists (1456) 1456
market positioning (1454) 1454
manufacturers (1446) 1446
equity (1393) 1393
prices and rates (1374) 1374
drugs, generic (1363) 1363
cases (1349) 1349
analysis (1333) 1333
collaboration (1324) 1324
short sales (1310) 1310
diabetes (1295) 1295
therapeutic equivalency (1256) 1256
bills (1239) 1239
economic aspects (1213) 1213
health care industry (1208) 1208
drugs, generic - therapeutic use (1200) 1200
hospitals (1186) 1186
narcotics (1158) 1158
drugstores (1153) 1153
public health (1129) 1129
pharmacy benefit management (1113) 1113
profits (1106) 1106
medicaid (1095) 1095
oncology (1085) 1085
medicine (1072) 1072
care and treatment (1057) 1057
medicine, general & internal (1047) 1047
patent infringement (1028) 1028
antibiotics (1020) 1020
webcasting (1018) 1018
medical care, cost of (1006) 1006
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (146) 146
Gerstein Science - Stacks (28) 28
Robarts - Stacks (12) 12
UofT at Mississauga - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
UofT at Scarborough - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Gerstein Science - Periodical Stacks (4) 4
Law (Bora Laskin) - Stacks (3) 3
Law (Bora Laskin) - Theses (3) 3
Robarts - Government Pubs (3) 3
Engineering & Comp. Sci. - Stacks (2) 2
Media Commons - Microtexts (2) 2
UTL at Downsview - May be requested (2) 2
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Reference (1) 1
Media Commons - Audio Visual (1) 1
OISE - Stacks (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT at Mississauga - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (105697) 105697
French (259) 259
Spanish (258) 258
German (136) 136
Japanese (133) 133
Portuguese (121) 121
Russian (91) 91
Chinese (57) 57
Swedish (53) 53
Danish (40) 40
Norwegian (38) 38
Hindi (31) 31
Korean (28) 28
Italian (17) 17
Hungarian (14) 14
Polish (14) 14
Czech (10) 10
Dutch (7) 7
Croatian (6) 6
Urdu (6) 6
Afrikaans (3) 3
Slovak (3) 3
Hebrew (2) 2
Lithuanian (2) 2
Turkish (2) 2
Ukrainian (2) 2
Arabic (1) 1
Bosnian (1) 1
Greek (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2017, ISBN 1107168481, xii, 151 pages
"While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic... 
Drugs | Generic drugs | Costs | Pharmaceutical policy | Pharmaceutical industry | Prices | United States
Book
2009, Health care issues, costs and access series, ISBN 9781606928431, 157
Book
2011, Biohealthcare Publishing series on pharma, biotech and biosciences., ISBN 1907568123, Volume 13., xx, 275
Book
Journal of generic medicines, ISSN 1741-1343, 2003
Journal
Journal
2002, Biostatistics, ISBN 082470763X, Volume 10, 378
Emphasizing the role of good statistical practices (GSP) in drug research and formulation, this book outlines important statistics applications for each stage... 
Drugs | standards | Data Interpretation, Statistical | Drug Stability | methods | Drug Design | Biological Availability | Pharmaceutical Preparations | Statistical methods | Research | Statistics | Therapeutic Equivalency
eBook
2010, Drugs and the pharmaceutical sciences, ISBN 9780849377860, Volume 204., xi, 275
Book
1998, ISBN 9780521584142, xiii, 269
All of us are drug users, in the broadest sense of the word. Drugs can be medicines, they can be used for pleasure, and they can also be used to protect our... 
Drugs | Médicaments | Mechanism of action | Mécanisme d'action
Book
2017, ISBN 1107168481
"While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic... 
Drug Costs | economics | United States | Drug Industry | Economic Competition | supply & distribution | legislation & jurisprudence | Patents as Topic | Drugs, Generic
Web Resource
2014, 2nd ed., Drugs and the pharmaceutical sciences, ISBN 9781420086355, Volume 129, xii, 385
"This book collects in-depth discussions from more than 30 noted specialists on topics such as quality control, experimental formulations, pharmaceutical... 
standards | Generic drugs | Tablets | Drug Approval | Chemistry, Pharmaceutical | Solid dosage forms | Drugs, Generic
Book
2002, World Bank discussion paper, ISBN 0821352121, Volume no. 437., xiii, 59 p. cm.
This report assesses the pharmaceutical sector in India, particularly focusing on four key issues related to the production, procurement, and distribution of... 
Drugs | Pharmaceutical policy | Pharmaceutical industry | Marketing | INFORMAL SECTOR | PHARMACY | PHARMACEUTICAL SERVICES | PHARMACEUTICAL MANUFACTURERS | PHYSICIANS | MEDICINAL DRUGS | DRUG UTILIZATION | DEVELOPED COUNTRIES | PHARMACISTS | HEALTH SECTOR | HUMAN DEVELOPMENT | PILL | VACCINES | NATIONAL DRUG POLICIES | NATIONAL DRUG POLICY | PRIVATE SECTOR | QUALITY CONTROL | GMP | LAWS | DISTRIBUTION OF PHARMACEUTICALS | PHARMACEUTICAL SUPPLY | NUTRITION | HEALTH CARE FINANCING | ADVERSE EFFECTS | PHARMACY CURRICULA | HOSPITALS | PHARMACEUTICAL COMPANIES | PHARMACEUTICAL POLICY | INCOME | DRUGS | INTERNATIONAL TRADE ACCOUNTING | NDP | HEALTH POLICY | TREATMENT GUIDELINES | THERAPEUTICS | PHARMACEUTICALS | PRODUCERS | MARKETING | PUBLIC EDUCATION | AVAILABILITY | PATENTS | SOCIAL SERVICES | SAFETY NETS | PHARMACEUTICALS PROCUREMENT | PUBLIC SECTOR | SAFETY | SANCTIONS | IRRATIONAL USE | ADVERTISING | INNOVATION | MEDICINES | PHARMACEUTICAL POLICIES | PHARMACEUTICAL SECTOR | DRUG LAW | DRUG INDUSTRY | PHARMACEUTICAL QUALITY ASSURANCE | DISCRIMINATION | GOVERNMENT REGULATIONS | GENERIC DRUGS | LOCAL PRODUCTION | PHARMACY SCHOOLS | PHARMACEUTICAL PATENTS | DRUG SELECTION | PHARMACEUTICAL RESEARCH | NURSING | DRUG PRICES | PHARMACEUTICAL QUALITY | AFFORDABILITY | TELECOMMUNICATIONS | COST SAVINGS | OIL | RATIONAL USE OF DRUGS | MEDICATION | INSURANCE | CERTIFICATION | DRUG CONTROL | PROCUREMENT | SOCIAL INSURANCE | MINISTRIES OF HEALTH | HUMAN BEHAVIOUR | PROPERTY RIGHTS | EXPENDITURES | IMPORTS | GENERIC SUBSTITUTION | BRAND NAME DRUGS | GOOD MANUFACTURING PRACTICES | HEALTH CARE SERVICES | LABORATORIES | PURCHASING | POLICY INSTRUMENTS | PHARMACEUTICAL INDUSTRY | SUSTAINABLE DEVELOPMENT | HEALTH CARE | ESSENTIAL DRUGS | ECONOMICS | HEALTH CARE COSTS | CONTRACTING OUT
Book
2010, Drugs and the pharmaceutical sciences, ISBN 0849377854, Volume 201., xxi, 309
Due to a worldwide need for lower cost drug therapy, use of generic and multi-source drug products have been increasing. To meet international patent and trade... 
Generic drugs | Law and legislation | Industrial chemistry & manufacturing technologies | Pharmaceutical Manufacturing | Pharmaceutical Science Regulatory | Drug Design & Development | Drugs | Therapeutic equivalency | Standards
Book
2010, Directions in development. Human development, ISBN 9780821383865, xxi, 215
This book discusses the wide range of challenges faced by policy makers in the pharmaceutical sector, presents the current know-how in terms of policy... 
economics | Developed Countries | Health Plan Implementation | Pharmaceutical policy | Drug Industry | Government Regulation | Health Policy | organization & administration | PHARMACY | INDUSTRIAL DEVELOPMENT | REGULATORY BARRIERS | SERVICE DELIVERY | PHYSICIANS | INTERNATIONAL AGREEMENTS | CITIZENSHIP | FIXED COSTS | HEALTH SECTOR | ABUSE | HUMAN DEVELOPMENT | PHARMACEUTICAL REGULATION | SUPPLY CHAIN | UNEMPLOYMENT RATES | ECONOMIC GROWTH | RETAIL PHARMACIES | GOOD GOVERNANCE | POLICY FRAMEWORK | PRIVATE PHARMACIES | PHARMACEUTICAL PROCUREMENT | PUBLIC POLICY | PRICE REGULATION | DIABETES | MEDICAL SUPPLIES | GMP | HEALTH SYSTEMS | BRIBERY | HEALTH WORKERS | PAYMENT TERMS | HEALTH SERVICES | MALARIA | PHARMACEUTICAL SUPPLY | HIGH BLOOD PRESSURE | TECHNICAL CAPACITY | MORTALITY | PATIENTS | FRAUD | BIOLOGICALS | CAPSULES | TUBERCULOSIS | HOSPITALS | NARCOTICS | SUPPLIER | DEVELOPING COUNTRIES | PHARMACEUTICAL POLICY | ACCOUNTABILITY | DECISION MAKING | HOME COUNTRIES | SALES | HEALTH POLICY | TURNOVER | TRANSPORTATION | DEMOCRACY | DOSAGE FORMS | MARKETING | HEALTH INSURANCE | MEDICAL SPECIALISTS | CHRONIC DISEASES | CLINICS | EDUCATION SYSTEMS | CENTRAL MEDICAL STORES | STOCKS | PURCHASING POWER | HEALTH OUTCOMES | REFORM EFFORT | COMPETITIVE BIDDING | MEDICINES | NATIONAL DRUG | CANCER | PHARMACEUTICAL POLICIES | NURSE | TABLETS | HEALTH CARE PROVIDERS | DRUG INDUSTRY | INVENTORY | DISCRIMINATION | DISTRIBUTION SYSTEMS | FAMILIES | CIVIL SOCIETY ORGANIZATIONS | DISABILITY | COMPLICATIONS | FAMILY MEMBERS | WHOLESALERS | CIF | DRUG PRICES | HEALTH SYSTEM | NATIONAL GOVERNMENT | CONSUMER GROUPS | BRAND | HUMAN IMMUNODEFICIENCY VIRUS | MEDICAL EDUCATION | MARKET ENTRY | HOSPITAL | OPERATING COSTS | CHEMISTS | SUPPLIERS | UNIVERSAL ACCESS | QUALITY ASSURANCE | LOCAL ECONOMY | ILLNESS | PROCUREMENT | RURAL AREAS | MEDICINE | GLOBAL DEVELOPMENT | REGULATORY AGENCIES | IMMUNIZATION | INDUSTRIAL PRODUCTION | CARDIOVASCULAR DISEASE | ENVIRONMENTAL PROTECTION | PROGRESS | URBAN POPULATION | GLOBAL POLICY | GOOD MANUFACTURING PRACTICES | INFORMATION SYSTEMS | LABORATORIES | DOMESTIC MANUFACTURERS | WORLD HEALTH ORGANIZATION | PACKAGING | RETAIL | CLINICAL TRIALS | POOLED PROCUREMENT | ACQUIRED IMMUNODEFICIENCY SYNDROME | POLITICAL DECISION | INTERMEDIARIES | HEALTH CARE | HEALTH CARE ACCESS | COMPETITIVENESS | PHARMACEUTICAL MANUFACTURERS | INVENTORY MANAGEMENT | CORRUPTION | PHARMACEUTICAL EXPENDITURE | CITIZENS | POLITICAL OPPOSITION | PRACTITIONERS | PHARMACISTS | LOW-INCOME COUNTRY | MEDICAL SCHOOL | NURSES | VACCINES | MEDICAL SERVICES | QUANTITATIVE DATA | WORKERS | NATIONAL LEGISLATION | QUALITY CONTROL | DEVELOPMENT GOALS | LAWS | PHARMACEUTICAL PRODUCTS | HEALTH CARE REFORM | MINISTRY OF HEALTH | DISSEMINATION | TRADE ISSUES | NUTRITION | POLITICAL SUPPORT | POLICY GOALS | PRESCRIPTIONS | USE OF RESOURCES | HEALTH CARE SYSTEM | PUBLIC HEALTH | RISK FACTORS | DEVELOPMENT POLICY | PUBLIC SUPPORT | PHARMACEUTICAL COMPANIES | PHARMACEUTICAL REFORM | LOCAL MANUFACTURERS | DRUGS | HEALTH MANAGEMENT | PHARMACEUTICALS | PHARMACEUTICAL MARKETS | PHARMACEUTICAL ¸ MANUFACTURERS | SERVICE QUALITY | HEALTH POLICIES | DEATH RATES | MANAGEMENT SYSTEMS | HIV | DRUG DONATIONS | LEGAL STATUS | MILLENNIUM DEVELOPMENT GOALS | PATIENT | HEALTH CENTERS | COMMODITIES | ESSENTIAL MEDICINES | MEDICAL NEEDS | PHARMACEUTICAL | IMPORTED DRUGS | PHARMACEUTICAL SECTOR | SUPPLY CHAINS | RESPECT | PERSONAL RELATIONSHIPS | POLICY DECISIONS | LIFE EXPECTANCY | GENERIC DRUGS | PHARMACOLOGISTS | LOW-INCOME COUNTRIES | WAREHOUSE | PHARMACIES | FUTURE GROWTH | PHARMACEUTICAL MARKETING | EMERGING MARKETS | RATIONAL USE OF DRUGS | HEALTH REFORM | IMMUNODEFICIENCY | SOCIAL SECURITY | DELIVERY SYSTEMS | FAVORITISM | DRUG CONTROL | INTERNATIONAL ORGANIZATIONS | SECURE SUPPLY | ILLNESSES | QUALITY OF CARE | CHILD MORTALITY | REGULATORY AUTHORITIES | MINISTRIES OF HEALTH | HEALTH FACILITIES | DONOR FINANCING | PHARMACEUTICAL PRICING | PURCHASING | UNEMPLOYMENT | GOVERNMENT AGENCIES | PHARMACEUTICAL INDUSTRY | PUBLIC HEALTH POLICY | POLICY MAKERS | WAREHOUSES | PHARMACEUTICAL PRICING POLICIES | BUDGETING | POLITICAL CHANGE | ESSENTIAL DRUGS | SERVICE PROVIDERS
Book
PLoS ONE, ISSN 1932-6203, 09/2011, Volume 6, Issue 9, pp. e23946 - e23946
Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a long-term follow-up of direct costs for... 
INDIVIDUALS | THERAPY | PRICE | DRUGS | EMTRICITABINE | BIOLOGY | INFECTION | STRATEGIES | REDUCE | LIFE | Anti-HIV Agents - pharmacology | Anti-HIV Agents - economics | Follow-Up Studies | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Drugs, Generic - economics | Reverse Transcriptase Inhibitors - pharmacology | Male | Drugs, Generic - therapeutic use | Protease Inhibitors - pharmacology | Drug Prescriptions - economics | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Protease Inhibitors - therapeutic use | Drugs, Generic - pharmacology | Reverse Transcriptase Inhibitors - economics | Protease Inhibitors - economics | Drug Therapy, Combination - economics | Drug Prescriptions - statistics & numerical data | HIV Infections - drug therapy | Cost Savings - statistics & numerical data | Germany | Cohort Studies | Highly active antiretroviral therapy | Medical research | Generic drugs | Protease inhibitors | Proteases | Analysis | Economic aspects | Medicine, Experimental | HIV (Viruses) | Health care | Drugs | Antiretroviral drugs | Therapy | Costs | Ritonavir | Medical treatment | Resource allocation | Medical services | Cost reduction | Data processing | Disease control | Antiretroviral therapy | Prescription drugs | Inhibitors | Taxes | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Taxation | Cost analysis | Cost engineering | Pharmaceuticals | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.